X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: ALPHA-1062
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $6.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 22, 2023
Details:
ALPHA-1062 (benzgalantamine), AChE inhibitor delayed-release oral tablet formulation. Currently being evaluated in the Phase III clinical trial studies for the treatment of mild-to-moderate Alzheimer’s Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: ALPHA-1062
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: ALPHA-1062
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $6.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 04, 2023
Details:
The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: ALPHA-1062
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Spartan Capital Securities
Deal Size: $6.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 08, 2023
Details:
The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: ALPHA-1062
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $97.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 16, 2023
Details:
ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: ALPHA-1062
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: ALPHA-1062
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 31, 2023
Details:
The net proceeds from the Offering are expected to be used for the advancement of the Company’s clinical development programs, to complete and file a New Drug Application for ALPHA-1062 (galantamine benzoate), and for general corporate purposes.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: ALPHA-1062
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Spartan Capital Securities
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 16, 2023
Details:
The Company expects to use the net proceeds from the Offering, for the advancement of the Company’s clinical development programs, complete and file a New Drug Application for ALPHA-1062 (galantamine benzoate), and for working capital and other general corporate purposes.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: ALPHA-1062
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Spartan Securities LLC
Deal Size: $4.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 16, 2023
Details:
The Company expects to use the net proceeds from the Offering, for the advancement of the Company’s clinical development programs, complete and file a New Drug Application for ALPHA-1062 (galantamine benzoate), and for working capital and other general corporate purposes.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: ALPHA-1062
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Spartan Capital Securities
Deal Size: $6.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 08, 2023
Details:
ALPHA-1062 (galantamine benzoate), is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: ALPHA-1062
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering November 28, 2022
Details:
ALPHA-1062 (galantamine benzoate), is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: Alpha-1062
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Topline results confirmed in fed and fasted bioequivalence studies that ALPHA-1062 achieved bioequivalent area-under-the-curve and peak exposures relative to galantamine hydrobromide IR.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: Alpha-1062
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
ALPHA-1062 is proprietary, delayed release tablet formulation designed to treat Alzheimer’s disease is being developed as a new generation of AChEI designed to improve existing therapy by overcoming gastrointestinal side effects and tolerability limitations.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Product Name: Alpha-1062
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
